183388-64-9

Basic information

• Product Name: (2S,3S,5S)-5-tert-Butyloxycarbonylamino-2-amino-3-hydroxy-1,6-diphenylhexane succinate
• Synonyms: (2S,3S,5S)-5-tert-Butyloxycarbonylamino-2-amino-3-hydroxy-1,6-diphenylhexne 1/2 succinate (BDH Succinate salt);(2S,3S,5S)-2-Amino-3-hydroxy-5-(tert-butyloxy carbonyl)amino-1,6-diphenylhexane succinate;(2S,3S,5S)-2-aMino-3-hydroxy-5-(tert-butyloxycarbonyl)aMino-1,6-diphenyl heMi succinic acid salt (BDH succinic acid salt);(2S,3S,5S)-2-aMino-3-hydroxy-5-(t-butyloxycarbonylaMino)-1,6-diphenylhexane heMi succinic acid salt;(2s,3s,5s)-5-tert-butyloxycarbonylaMino-2-aMino-3-hydroxy-1,6-diphenylhexane succinate(BDH Succinate Salt);BDH SUCCINIC ACID SALT;bdh succinate salt;(2s,3s,5s)-5-tert-butyloxycarbonylamino-2-amino-3-hydroxy-1,6-diphenylhexane succinate
• CAS NO: 183388-64-9
• Molecular Formula: 2C23H32N2O3.C4H6O4
• Molecular Weight: 887.12
• Mol File: 183388-64-9.mol

Chemical Properties

• Boiling Point: 569.2ºC at 760 mmHg
• Flash Point: 298ºC
• Appearance: /
• Vapor Pressure: 8.56E-14mmHg at 25°C
• CAS DataBase Reference: (2S,3S,5S)-5-tert-Butyloxycarbonylamino-2-amino-3-hydroxy-1,6-diphenylhexane succinate(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,3S,5S)-5-tert-Butyloxycarbonylamino-2-amino-3-hydroxy-1,6-diphenylhexane succinate(183388-64-9)
• EPA Substance Registry System: (2S,3S,5S)-5-tert-Butyloxycarbonylamino-2-amino-3-hydroxy-1,6-diphenylhexane succinate(183388-64-9)

Safety Data

• Hazardous Substances Data: 183388-64-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(2S,3S,5S)-5-tert-Butyloxycarbonylamino-2-amino-3-hydroxy-1,6-diphenylhexane succinate is used as a potential candidate for drug development due to its unique molecular structure and the possibility of exhibiting biological activity that could be harnessed for therapeutic purposes.
Further applications may be discovered as research progresses, but currently, the primary focus is on its potential within the pharmaceutical sector for creating new drugs that could address various health conditions. (2S,3S,5S)-5-tert-Butyloxycarbonylamino-2-amino-3-hydroxy-1,6-diphenylhexane succinate's specific uses will depend on the results of ongoing studies and its demonstrated efficacy and safety in preclinical and clinical trials.

InChI:InChI=1/C23H32N2O3.C4H6O4/c1-23(2,3)28-22(27)25-19(14-17-10-6-4-7-11-17)16-21(26)20(24)15-18-12-8-5-9-13-18;5-3(6)1-2-4(7)8/h4-13,19-21,26H,14-16,24H2,1-3H3,(H,25,27);1-2H2,(H,5,6)(H,7,8)/t19-,20-,21-;/m0./s1

Upstream product

• 110-15-6 succinic acid 
• 63-91-2 L-phenylalanine 
• 144163-85-9 (2S,3S,5S)-2-amino-3-hydroxy-5-(t-butyloxycarbonylamino)-1,6-diphenylhexane 

Downstream Products

• 192725-45-4 (2S,3S,5S)-2-(2,6-dimethylphenoxyacetyl)amino-3-hydroxy-5-(t-butyloxycarbonylamino)-1,6-diphenylhexane 

Relevant articles and documents

Diastereoselective synthesis of a core fragment of ritonavir and lopinavir

A novel approach to the synthesis of Boc-core, a key starting material for ritonavir and lopinavir involving an unprecedented diastereoselective nitroaldol reaction on β-amino aldehyde is disclosed.

A PROCESS FOR THE SYNTHESIS OF 2-AMINO-5-PROTECTED AMINO-3-HYDROXY-1, 6-DIPHENYLHEXANE OR A SALT THEREOF - AN INTERMEDIATE FOR ANTIVIRAL DRUGS

The present invention relates to an improved process for preparing 2-amino-5-protected-amino-3-hydroxy-1,6-diphenylhexane compounds or acid addition salts thereof, which can be useful intermediates for preparing compounds with antiviral activity. The present invention further provides a process for preparing HIV protease inhibitors, lopinavir and ritonavir.

HIV protease inhibiting compounds

A compound of the formula is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.

Retroviral protease inhibiting compounds

A compound comprising a substituent of the formula (II) is disclosed as an HIV protease inhibitor. Intermediates for making such compounds and processes for making such intermediates are also disclosed.

RETROVIRAL PROTEASE INHIBITING COMPOUNDS

A compound of the formula: STR1 is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.

Process for the preparation of a substituted 2,5-diamino-3-hydroxyhexane

Intermediates and processes are disclosed which are useful for the preparation of a substantially pure compound of the formula: STR1 wherein R6 and R7 are each hydrogen or R6 and R7 are independently selected from STR2 wherein Ra and Rb are independently selected from hydrogen, loweralkyl and phenyl and Rc, Rd and Re are independently selected from hydrogen, loweralkyl, trifluoromethyl, alkoxy, halo and phenyl; and STR3 wherein the naphthyl ring is unsubstituted or substituted with one, two or three substitutents independently selected from loweralkyl, trifluoromethyl, alkoxy and halo; or R6 is as defined above and R7 is R7a OC(O)--wherein R7a is loweralkyl or benzyl; or R6 and R7 taken together with the nitrogen atom to which they are bonded are STR4 wherein Rf, Rg, Rh and Ri are independently selected from hydrogen, loweralkyl, alkoxy, halogen and trifluoromethyl and R8 is hydrogen or --C(O)R" wherein R" is loweralkyl, alkoxy, benzyloxy or phenyl wherein the phenyl ring is unsubstituted or substituted with one, two or three substituents independently selected from loweralkyl, trifluoromethyl, alkoxy and halo; or an acid addition salt thereof.